MW 284
Latest Information Update: 13 Jul 2000
At a glance
- Originator Novartis
- Class Antirheumatics
- Mechanism of Action Interleukin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 13 Jul 2000 No-Development-Reported for Rheumatic disorders (Unknown route)